Clinical Trials
20 trialsNCT03547700 2026-05-06
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT01846390 2026-03-27
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 1 Completed
NCT04447027 2026-01-30
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02223208 2025-12-02
FIL_PTCL13
Fondazione Italiana Linfomi - ETS
Phase 1/2 Active not recruiting
NCT02512497 2025-09-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01998035 2024-08-22
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT02232516 2024-04-10
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT03742921 2023-12-06
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
Celgene
Completed
NCT01796002 2023-01-10
Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT01947140 2022-11-23
PDX+Romi
Columbia University
Phase 1/2 Completed
NCT03141203 2022-05-18
RomiCar
University of Birmingham
Phase 1/2 Completed
NCT02181218 2020-11-17
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Washington University School of Medicine
Phase 1 Completed
NCT00426764 2020-02-11
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Celgene
Phase 2 Completed
NCT01822886 2019-10-14
FIL_GEMRO
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT01456039 2019-02-11
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
Celgene
Phase 1/2 Completed
NCT03355768 2018-12-19
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
Columbia University
Phase 3 Withdrawn
NCT01482962 2018-07-31
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Takeda
Phase 3 Completed
NCT00963274 2018-04-23
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Virginia Commonwealth University
Phase 1 Completed
NCT00007345 2017-05-16
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01280526 2014-05-22
Ro-CHOP
The Lymphoma Academic Research Organisation
Phase 1/2 Completed